In left ventricular failure, which medications should be administered and which should be avoided?

Left Ventricular Failure: Medication Management

What TO Give

All patients with LVF and reduced ejection fraction should receive ACE inhibitors and beta-blockers as foundational therapy, with diuretics added for fluid overload—this combination reduces mortality and hospitalization rates. 1, 2, 3

First-Line Medications (Class I Recommendations)

ACE Inhibitors:

• Indicated for ALL patients with reduced LVEF unless contraindicated 4, 1, 3
• Start low, titrate to target doses proven in trials
• Monitor renal function and potassium at 1-2 weeks after each dose increase, then at 3 months, then every 6 months 5
• If intolerable due to cough or angioedema, substitute with ARBs 1, 2

Beta-Blockers:

• Use ONLY evidence-based agents: bisoprolol, carvedilol, metoprolol succinate, or nebivolol 2
• Indicated for all symptomatic patients (NYHA II-IV) with reduced LVEF 1, 5, 3
• "Start low, go slow" approach with monitoring after each titration 2
• Do NOT avoid in elderly, diabetes, COPD, or peripheral vascular disease—these patients benefit equally 2

Diuretics:

• Essential for patients with fluid retention/congestion 1, 3
• Loop diuretics (furosemide, bumetanide, torsemide) are first-line 1
• Always combine with ACE inhibitors 5
• For refractory cases: combine loop diuretics with thiazides (metolazone) or use twice-daily dosing 1, 5

Second-Line Medications

Aldosterone Antagonists (Spironolactone/Eplerenone):

• Add for patients with NYHA III-IV symptoms despite ACE inhibitor + beta-blocker + diuretic 1, 5, 3
• Requires close monitoring: serum creatinine ≤2.5 mg/dL (men) or ≤2.0 mg/dL (women), potassium <5.0 mEq/L 6
• Check potassium and creatinine every 5-7 days initially 5

Sacubitril/Valsartan:

• Replace ACE inhibitor in ambulatory patients who remain symptomatic on optimal therapy 3
• Reduces HF hospitalization and death beyond ACE inhibitors alone

Digoxin:

• Use in atrial fibrillation with rapid ventricular rate 4, 1
• Consider in severe systolic dysfunction (NYHA III-IV) in sinus rhythm if inadequate response to other therapies 4, 1
• Avoid in diastolic dysfunction with normal LVEF and sinus rhythm 7, 8

Hydralazine + Isosorbide Dinitrate:

• For patients who cannot tolerate ACE inhibitors or ARBs 4, 1, 2
• Third-line option if inadequate response to ACE inhibitor + beta-blocker 2

---

What NOT to Give

Calcium Channel Blockers (Diltiazem, Verapamil):

• Class III recommendation (harmful) in HFrEF 4, 3
• Increase risk of HF worsening and hospitalization due to negative inotropic effects 1, 3
• Exception: Second-generation dihydropyridines (amlodipine) may be used cautiously for refractory hypertension or angina 5

NSAIDs:

• Avoid or withdraw—cause fluid retention and worsen HF 1, 5, 9
• Interfere with ACE inhibitor efficacy 5

Most Antiarrhythmic Drugs:

• Avoid except amiodarone for severe symptomatic ventricular tachycardia 1, 5, 6
• Class I antiarrhythmics increase mortality

Triple Renin-Angiotensin-Aldosterone System Blockade:

• Do NOT combine ACE inhibitor + ARB + aldosterone antagonist 3
• Increases risk of hyperkalemia and renal dysfunction 2

Medications That Exacerbate HF:

• Albuterol (used in 34.9% of ADHF patients despite risks) 9
• Metformin and other diabetes medications in decompensated states 9
• Tamsulosin and urologic agents 9

---

Critical Monitoring Points

When Starting ACE Inhibitors:

• Reduce or hold diuretics 24 hours before initiation to avoid hypotension 5
• Avoid potassium-sparing diuretics during initiation 5
• Check BP, renal function, electrolytes at 1-2 weeks, then regularly 5

QT-Prolonging Medications:

• 82.9% of ADHF patients receive QT-prolonging drugs (loop diuretics, amiodarone, ondansetron) 9
• Avoid combining multiple QT-prolonging agents when possible—42.1% receive >2 concomitantly, increasing torsades risk 9

---

Special Considerations

Diastolic Dysfunction (HFpEF):

• Beta-blockers and ACE inhibitors for rate control and hypertension 5
• Diuretics for congestion 7, 8
• Avoid digoxin in sinus rhythm 7, 8
• Verapamil may be used cautiously (unlike in systolic dysfunction) 5

Atrial Fibrillation:

• Digoxin, beta-blockers, or verapamil/diltiazem for rate control 5, 8
• Anticoagulation mandatory 4

Post-MI with LV Dysfunction:

• Beta-blockers + ACE inhibitors reduce mortality 4, 5
• Consider aldosterone antagonist if LVEF ≤40% with diabetes or HF 10

The evidence consistently demonstrates that adherence to guideline-directed medical therapy with ACE inhibitors, beta-blockers, and diuretics forms the cornerstone of LVF management, while calcium channel blockers and NSAIDs represent clear contraindications that worsen outcomes.